TransCode Therapeutics, Inc. has received two deficiency letters from The Nasdaq Stock Market. The first, received on August 13, 2024, notified the company of its failure to meet the Minimum Bid Price Requirement, as its common stock did not maintain the required $1.00 per share minimum closing bid price for 30 consecutive business days. The second letter, received on August 15, 2024, indicated a deficiency in meeting the Stockholders' Equity Requirement, with reported equity of $1,322,274, below the required $2,500,000. TransCode Therapeutics plans to request a hearing before the Nasdaq Hearings Panel to address these deficiencies and has reported pro forma stockholders' equity of approximately $3.7 million, considering net proceeds from a July 2024 equity offering. The company's securities are at risk of suspension or delisting, and there is no assurance that the Panel will grant an extension or that the company will regain compliance with Nasdaq's continued listing requirements.

TransCode Therapeutics, Inc. has received two deficiency letters from The Nasdaq Stock Market. The first, received on August 13, 2024, notified the company of its failure to meet the Minimum Bid Price Requirement, as its common stock did not maintain the required $1.00 per share minimum closing bid price for 30 consecutive business days. The second letter, received on August 15, 2024, indicated a deficiency in meeting the Stockholders' Equity Requirement, with reported equity of $1,322,274, below the required $2,500,000. TransCode Therapeutics plans to request a hearing before the Nasdaq Hearings Panel to address these deficiencies and has reported pro forma stockholders' equity of approximately $3.7 million, considering net proceeds from a July 2024 equity offering. The company's securities are at risk of suspension or delisting, and there is no assurance that the Panel will grant an extension or that the company will regain compliance with Nasdaq's continued listing requirements.